Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Up 4.9% – Here’s Why

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF)’s share price was up 4.9% on Monday . The company traded as high as $0.45 and last traded at $0.44. Approximately 5,500 shares were traded during trading, an increase of 153% from the average daily volume of 2,175 shares. The stock had previously closed at $0.42.

Sino Biopharmaceutical Trading Up 0.9 %

The business has a 50 day simple moving average of $0.41 and a 200-day simple moving average of $0.42. The company has a quick ratio of 1.07, a current ratio of 1.15 and a debt-to-equity ratio of 0.02.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.